SG11201808237UA - Substituted indole compound derivatives as dengue viral replication inhibitors - Google Patents
Substituted indole compound derivatives as dengue viral replication inhibitorsInfo
- Publication number
- SG11201808237UA SG11201808237UA SG11201808237UA SG11201808237UA SG11201808237UA SG 11201808237U A SG11201808237U A SG 11201808237UA SG 11201808237U A SG11201808237U A SG 11201808237UA SG 11201808237U A SG11201808237U A SG 11201808237UA SG 11201808237U A SG11201808237U A SG 11201808237UA
- Authority
- SG
- Singapore
- Prior art keywords
- leuven
- international
- compounds
- dengue viral
- turnhoutseweg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111 HO 11111 0111011110011111H101011111110111011 1111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/167952 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: (74) Agent: VERBERCKMOES, Mr. Filip; J&J Patent Law A61K 31/404 (2006.01) C07F 9/00 (2006.01) Department Turnhoutseweg 30, 2340 Beerse (BE). A61P 31/12 (2006.01) C07D 491/048 (2006.01) C07D 209/14 (2006.01) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, PCT/EP2017/057662 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 31 March 2017 (31.03.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (25) Filing Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (30) Priority Data: TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 16163482.9 1 April 2016 (01.04.2016) EP ZA, ZM, ZW. (71) Applicants: JANSSEN PHARMACEUTICALS, INC. (84) Designated States (unless otherwise indicated, for every [US/US]; 1125 Trenton-Harbourton Road, Titusville, NJ kind of regional protection available): ARIPO (BW, GH, New Jersey 08560 (US). KATHOLIEKE UNI- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, VERSITEIT LEUVEN [BE/BE]; Waaistraat 6, bus 5105, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 3000 Leuven (BE). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: BARDIOT, Dorothee Alice Marie-Eve; c/o LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, — Cistim Leuven vzw Gaston Geenslaan 2, 3001 Leuven SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, _ (Heverlee) (BE). BONFANTI, Jean-Francois; c/o GW, KM, ML, MR, NE, SN, TD, TG). Janssen-Cilag 1 rue Camille Desmoulins, TSA 91003, = 92787 Issy-les-Moulineaux Cedex 9 (FR). COESEMANS, Declarations under Rule 4.17: Erwin; Janssen Pharmaceutica NV Turnhoutseweg 30, — be c/o as to applicant's entitlement to apply for and granted a 2340 Beerse (BE). KESTELEYN, Bart Rudolf Romanie; patent (Rule 4.1700) = c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 — Beerse (BE). MARCHAND, Arnaud Didier M; c/o Cis- Published: Leuven Gaston Geenslaan 2, 3001 Leuven — international 21(3)) tim vzw (Hever- with search report (Art. lee) (BE). RABOISSON, Pierre Jean-Marie Bernard; with sequence listing part of description (Rule 5.2(a)) = c/o Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 = Beerse (BE). = = = = = = = = 1-1 ei kr) 0\ IN 1-1 (54) Title: SUBSTITUTED INDOLE COMPOUND DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS 1-1 © (57) : The present invention concerns substituted indole compounds, methods to prevent or treat dengue viral infections by N using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or 0 prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination prepara- tions of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163482 | 2016-04-01 | ||
| PCT/EP2017/057662 WO2017167952A1 (en) | 2016-04-01 | 2017-03-31 | Substituted indole compound derivatives as dengue viral replication inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808237UA true SG11201808237UA (en) | 2018-10-30 |
Family
ID=55650310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808237UA SG11201808237UA (en) | 2016-04-01 | 2017-03-31 | Substituted indole compound derivatives as dengue viral replication inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10730884B2 (en) |
| EP (1) | EP3436004B1 (en) |
| JP (2) | JP7007290B2 (en) |
| KR (1) | KR102359766B1 (en) |
| CN (1) | CN109069482B (en) |
| AU (1) | AU2017240076A1 (en) |
| BR (1) | BR112018068956A2 (en) |
| CA (1) | CA3013408A1 (en) |
| CL (1) | CL2018002784A1 (en) |
| CO (1) | CO2018009996A2 (en) |
| CR (1) | CR20180494A (en) |
| EA (1) | EA201892200A1 (en) |
| EC (1) | ECSP18073264A (en) |
| ES (1) | ES3010298T3 (en) |
| IL (1) | IL261947A (en) |
| MA (1) | MA44502A (en) |
| MX (1) | MX2018011786A (en) |
| PH (1) | PH12018502026A1 (en) |
| SG (1) | SG11201808237UA (en) |
| SV (1) | SV2018005750A (en) |
| WO (1) | WO2017167952A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (en) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JOP20160198B1 (en) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever |
| JO3633B1 (en) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever |
| BR112018068676A2 (en) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | substituted indole derivatives as dengue viral replication inhibitors |
| BR112018069601A2 (en) | 2016-03-31 | 2019-01-29 | Janssen Pharmaceuticals Inc | substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20170069B1 (en) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| BR112018068956A2 (en) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | substituted indole derivatives as dengue viral replication inhibitors |
| JOP20180026A1 (en) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | Indolein derivatives substituted as viral reproductive inhibitors of Fennec fever |
| JOP20180025B1 (en) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| EP3630723B1 (en) | 2017-05-22 | 2022-08-24 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| UA125970C2 (en) | 2017-05-22 | 2022-07-20 | Янссен Фармасьютікалз, Інк. | SUBSTITUTED INDOLINE DERIVATIVES AS DENGE VIRUS REPLICATION INHIBITORS |
| CN108586404A (en) * | 2018-06-12 | 2018-09-28 | 湖南大学 | A kind of synthetic method of N- aryl naphtho- furanone imine compound |
| CN108947948B (en) * | 2018-06-12 | 2021-07-20 | 湖南大学 | A kind of N-aryl naphthofuranone imine compound and its synthetic method |
| WO2026057013A1 (en) * | 2024-09-14 | 2026-03-19 | 华武生物医药技术(湖北)有限责任公司 | Dengue virus replication inhibitor, preparation method therefor and use thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| AU2002364566B2 (en) | 2001-12-12 | 2009-03-26 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating HSP90 binding activity |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| KR20070058602A (en) * | 2004-09-30 | 2007-06-08 | 티보텍 파마슈티칼즈 리미티드 | HCC inhibition bi-cyclic pyrimidine |
| CN101103026A (en) | 2005-01-14 | 2008-01-09 | 健亚生物科技公司 | Indole derivatives for the treatment of viral infections |
| KR20070102741A (en) | 2005-02-09 | 2007-10-19 | 미게닉스 인코포레이티드 | Compositions and methods for treating or preventing Flaviviridae infections |
| JP5715820B2 (en) * | 2007-09-18 | 2015-05-13 | スタンフォード ユニバーシティー | Methods for treating infections with Flaviviridae family viruses and compositions for treating infections with Flaviviridae family viruses |
| AP2010005480A0 (en) | 2008-06-03 | 2010-12-31 | Siga Technologies Inc | Small molecule inhibitors for the treatment or prevention of denque virus infection. |
| US8143259B2 (en) | 2008-08-19 | 2012-03-27 | Janssen Pharmaceutica, Nv | Cold menthol receptor antagonists |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| US8524764B2 (en) | 2010-01-15 | 2013-09-03 | Gilead Sciences, Inc. | Inhibitors of Flaviviridae viruses |
| GB201116559D0 (en) * | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| CA2923712C (en) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| SG10201908467RA (en) | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| ME03360B (en) * | 2014-10-01 | 2019-10-20 | Janssen Pharmaceuticals Inc | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS INHIBITORS OF DENGE VIRUS REPLICATION |
| NO2721243T3 (en) | 2014-10-01 | 2018-10-20 | ||
| MX2017004298A (en) * | 2014-10-01 | 2017-07-19 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indoles as dengue viral replication inhibitors. |
| PH12017501272B1 (en) | 2015-01-16 | 2023-01-11 | Janssen Pharmaceuticals Inc | Indole derivatives as dengue viral replication inhibitors |
| AR103680A1 (en) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | BACE1 SELECTIVE INHIBITORS |
| JOP20160086B1 (en) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JO3633B1 (en) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever |
| JOP20160198B1 (en) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever |
| RU2761212C2 (en) | 2015-11-03 | 2021-12-06 | Зоэтис Сервисиз Ллс | Polymer composites obtained by sol-gel method, and their application |
| BR112018069601A2 (en) | 2016-03-31 | 2019-01-29 | Janssen Pharmaceuticals Inc | substituted indoline derivatives as dengue viral replication inhibitors |
| BR112018068676A2 (en) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | substituted indole derivatives as dengue viral replication inhibitors |
| EA036637B1 (en) | 2016-03-31 | 2020-12-02 | Такеда Фармасьютикал Компани Лимитед | Heterocyclic spiro compounds inhibiting monoacylglycerol lipase |
| MX379513B (en) | 2016-04-01 | 2025-03-11 | Signal Pharm Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| JOP20170069B1 (en) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| CA3019650C (en) | 2016-04-01 | 2023-07-25 | Kite Pharma, Inc. | Chimeric receptors and methods of use thereof |
| AU2017242539B2 (en) | 2016-04-01 | 2020-10-15 | Basf Se | Bicyclic compounds |
| ES2891578T3 (en) | 2016-04-01 | 2022-01-28 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
| BR112018068956A2 (en) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | substituted indole derivatives as dengue viral replication inhibitors |
| IL262061B2 (en) | 2016-04-01 | 2023-03-01 | Amgen Inc | Chimeric receptors to flt3 and methods of use thereof |
| JOP20180026A1 (en) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | Indolein derivatives substituted as viral reproductive inhibitors of Fennec fever |
| JOP20180025B1 (en) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| UA125970C2 (en) | 2017-05-22 | 2022-07-20 | Янссен Фармасьютікалз, Інк. | SUBSTITUTED INDOLINE DERIVATIVES AS DENGE VIRUS REPLICATION INHIBITORS |
| EP3630723B1 (en) | 2017-05-22 | 2022-08-24 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
-
2017
- 2017-03-31 BR BR112018068956A patent/BR112018068956A2/en not_active Application Discontinuation
- 2017-03-31 CA CA3013408A patent/CA3013408A1/en not_active Abandoned
- 2017-03-31 CR CR20180494A patent/CR20180494A/en unknown
- 2017-03-31 JP JP2018549980A patent/JP7007290B2/en active Active
- 2017-03-31 MX MX2018011786A patent/MX2018011786A/en unknown
- 2017-03-31 EP EP17714752.7A patent/EP3436004B1/en active Active
- 2017-03-31 AU AU2017240076A patent/AU2017240076A1/en not_active Abandoned
- 2017-03-31 US US16/088,198 patent/US10730884B2/en active Active
- 2017-03-31 MA MA044502A patent/MA44502A/en unknown
- 2017-03-31 EA EA201892200A patent/EA201892200A1/en unknown
- 2017-03-31 SG SG11201808237UA patent/SG11201808237UA/en unknown
- 2017-03-31 KR KR1020187027650A patent/KR102359766B1/en active Active
- 2017-03-31 CN CN201780022068.1A patent/CN109069482B/en active Active
- 2017-03-31 ES ES17714752T patent/ES3010298T3/en active Active
- 2017-03-31 WO PCT/EP2017/057662 patent/WO2017167952A1/en not_active Ceased
-
2018
- 2018-09-21 CO CONC2018/0009996A patent/CO2018009996A2/en unknown
- 2018-09-21 PH PH12018502026A patent/PH12018502026A1/en unknown
- 2018-09-26 IL IL261947A patent/IL261947A/en unknown
- 2018-09-28 EC ECSENADI201873264A patent/ECSP18073264A/en unknown
- 2018-09-28 SV SV2018005750A patent/SV2018005750A/en unknown
- 2018-09-28 CL CL2018002784A patent/CL2018002784A1/en unknown
-
2021
- 2021-10-15 JP JP2021169228A patent/JP2022009166A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3013408A1 (en) | 2017-10-05 |
| CL2018002784A1 (en) | 2018-12-14 |
| SV2018005750A (en) | 2018-11-15 |
| JP2019511502A (en) | 2019-04-25 |
| ECSP18073264A (en) | 2018-10-31 |
| ES3010298T3 (en) | 2025-04-02 |
| EA201892200A1 (en) | 2019-03-29 |
| JP2022009166A (en) | 2022-01-14 |
| AU2017240076A1 (en) | 2018-08-09 |
| JP7007290B2 (en) | 2022-01-24 |
| CR20180494A (en) | 2019-01-29 |
| PH12018502026A1 (en) | 2019-02-11 |
| CO2018009996A2 (en) | 2018-09-28 |
| MX2018011786A (en) | 2019-05-20 |
| KR20180130502A (en) | 2018-12-07 |
| IL261947A (en) | 2018-10-31 |
| US10730884B2 (en) | 2020-08-04 |
| MA44502A (en) | 2019-02-06 |
| WO2017167952A1 (en) | 2017-10-05 |
| KR102359766B1 (en) | 2022-02-07 |
| CN109069482A (en) | 2018-12-21 |
| EP3436004C0 (en) | 2024-12-11 |
| BR112018068956A2 (en) | 2019-01-22 |
| EP3436004A1 (en) | 2019-02-06 |
| CN109069482B (en) | 2022-04-05 |
| EP3436004B1 (en) | 2024-12-11 |
| US20190276467A1 (en) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201809708PA (en) | Physiologically balanced injectable formulations of fosnetupitant |